Codiak BioSciences, Inc.
CDAKDelisted May 2, 2023- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001659352
Codiak BioSciences, Inc. was delisted on May 2, 2023; its insiders filed their last Form 4 on Mar 30, 2023; 27 institutions reported holding it in 13F filings for Q1 2023, worth $1.44M in total; no superinvestor held it.
13F holders, Q2 2023
Institutional positions in Codiak BioSciences, Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
CDAK is no longer listed, and 13F filings after Q1 2023 list far fewer holders. See Q1 2023
- Institutional holders
- 1
- −26 vs. Q1 2023
- Shares held
- 23.9K
- −8.22M (−99.7%) vs. Q1 2023
- Total value
- $0
- −$1.44M (−100.0%) vs. Q1 2023
- New holders
- 0
- 0 more added
- Sold out
- 26
- 0 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CDAK on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 1 | $0 |
| Q1 2023 | 27 | $1.44M |
| Q4 2022 | 40 | $5.76M |
| Q3 2022 | 48 | $13.6M |
| Q2 2022 | 49 | $33.9M |
| Q1 2022 | 62 | $86.5M |
| Q4 2021 | 51 | $145.4M |
| Q3 2021 | 56 | $223.6M |
| Q2 2021 | 52 | $259.9M |
| Q1 2021 | 47 | $187.7M |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Codiak BioSciences, Inc.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Acadian Asset Management LLC | 23,915 | $0 | 0.00% | 00.0% | Unchanged |
| Flagship Pioneering Inc. | 0 | $0 | 0.00% | −3,540,636−100.0% | Sold out |
| Laurion Capital Management LP | 0 | $0 | 0.00% | −2,013,300−100.0% | Sold out |
| University of Texas/Texas Am Investment Managment Co | 0 | $0 | 0.00% | −847,108−100.0% | Sold out |
| Vanguard Group Inc | 0 | $0 | 0.00% | −580,770−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −448,539−100.0% | Sold out |
| Ensign Peak Advisors, Inc | 0 | $0 | 0.00% | −252,782−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −161,957−100.0% | Sold out |
| Forefront Analytics, LLC | 0 | $0 | 0.00% | −110,210−100.0% | Sold out |
| Parametrica Management Ltd | 0 | $0 | 0.00% | −65,098−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −53,055−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −30,566−100.0% | Sold out |
| HighTower Advisors, LLC | 0 | $0 | 0.00% | −20,328−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −21,826−100.0% | Sold out |
| Pathstone Family Office, LLC | 0 | $0 | 0.00% | −17,000−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −15,334−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −12,740−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −10,491−100.0% | Sold out |
| National Asset Management, Inc. | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −7,165−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −667−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −332−100.0% | Sold out |
| US Bancorp | 0 | $0 | 0.00% | −300−100.0% | Sold out |
| Investors Research Corp | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −91−100.0% | Sold out |
| Salem Investment Counselors Inc | 0 | $0 | 0.00% | −50−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −79−100.0% | Sold out |